Emerging therapies targeting IL-36R, such as spesolimab and imsidolimab, showed promising results in clinical trials in terms of efficacy and safety and may improve the management of GPP in the future [46]. This evidence concerns the gene IL1RL2 and psoriasis 14, pustular.